WO2024128107A1 - Mélange maître, composition de résine, article moulé et ses procédés de production - Google Patents

Mélange maître, composition de résine, article moulé et ses procédés de production Download PDF

Info

Publication number
WO2024128107A1
WO2024128107A1 PCT/JP2023/043751 JP2023043751W WO2024128107A1 WO 2024128107 A1 WO2024128107 A1 WO 2024128107A1 JP 2023043751 W JP2023043751 W JP 2023043751W WO 2024128107 A1 WO2024128107 A1 WO 2024128107A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibacterial
antiviral agent
thermoplastic resin
parts
fatty acid
Prior art date
Application number
PCT/JP2023/043751
Other languages
English (en)
Japanese (ja)
Inventor
悠太 山岡
洋輝 後藤
幸介 藤田
宏明 中野
Original Assignee
Dic株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dic株式会社 filed Critical Dic株式会社
Publication of WO2024128107A1 publication Critical patent/WO2024128107A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P3/00—Fungicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/94—Bismuth compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/20—Compounding polymers with additives, e.g. colouring
    • C08J3/22—Compounding polymers with additives, e.g. colouring using masterbatch techniques
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/09—Carboxylic acids; Metal salts thereof; Anhydrides thereof
    • C08K5/098—Metal salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L101/00—Compositions of unspecified macromolecular compounds

Definitions

  • This disclosure relates to masterbatches, resin compositions, molded articles, and methods for producing the same.
  • Silver carriers particularly silver-loaded zirconium phosphate, are known as antibacterial and antiviral agents (see, for example, Patent Document 1), and are known to be used in combination with plastics such as polyester and polystyrene.
  • the problem that the invention aims to solve is to provide a molded article that combines excellent antibacterial and antiviral properties, transparency and surface appearance, a thermoplastic resin composition that can provide the molded article and has excellent processability, and a method for producing them.
  • the second problem that the invention aims to solve is to provide a masterbatch that can provide the thermoplastic resin composition, and a method for producing the masterbatch.
  • thermoplastic resin composition containing a specific fatty acid metal salt or metal complex can provide a molded article that combines excellent antibacterial properties, antiviral properties, transparency, and surface appearance, thereby solving the above problems.
  • thermoplastic resin composition produced using a masterbatch containing a thermoplastic resin and a specific fatty acid metal salt or metal complex can provide a molded article that combines excellent antibacterial properties, antiviral properties, transparency, and surface appearance, thereby solving the above problems.
  • the present disclosure provides a masterbatch containing a thermoplastic resin and an antibacterial and antiviral agent
  • the antibacterial and antiviral agent is contained in an amount of 0.03 to 90 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the masterbatch, or the content of the metal derived from the antibacterial and antiviral agent is contained in an amount of 0.0015 to 45 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the masterbatch
  • the present invention relates to a master batch characterized in that the antibacterial and antiviral agent is one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and a fatty acid metal salt, and the metals in the fatty acid metal salt, the metal complex of a heteroatom-containing compound ligand and
  • the present disclosure also provides a masterbatch containing a thermoplastic resin and an antibacterial and antiviral agent,
  • the antibacterial and antiviral agent is contained in an amount of 0.03 to 90 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the masterbatch;
  • the antibacterial and antiviral agent may be one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and a fatty acid metal salt, and the metals in the fatty acid metal salt, the metal complex of a heteroatom-containing compound ligand and a metal ion, and the metal complex of a heteroatom-containing compound ligand and a fatty acid metal salt may each independently be a lanthanoid, bismuth, manganese, magnesium, lead, yttrium, cobalt, or copper.
  • the present disclosure also provides a masterbatch containing a thermoplastic resin and an antibacterial and antiviral agent, the content of the metal derived from the antibacterial and antiviral agent is in the range of 0.0015 to 45 parts by mass per 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent in the masterbatch;
  • the antibacterial and antiviral agent may be one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and a fatty acid metal salt, and the metals in the fatty acid metal salt, the metal complex of a heteroatom-containing compound ligand and a metal ion, and the metal complex of a heteroatom-containing compound ligand and a fatty acid metal salt may each independently be a lanthanoid, bismuth, manganese, magnesium, lead, yttrium, cobalt, or copper.
  • the present disclosure relates to the masterbatch described in [1], in which the metal of the fatty acid metal salt, the metal of the metal complex of the heteroatom-containing compound ligand and a metal ion, and the metal of the metal complex of the heteroatom-containing compound ligand and a fatty acid metal salt are each independently a lanthanoid, bismuth, manganese, or magnesium.
  • the present disclosure relates to a masterbatch according to any one of [1] to [2], in which the fatty acid metal salt is a metal salt of a fatty acid having 2 to 31 carbon atoms.
  • the present disclosure relates to a masterbatch according to any one of [1] to [3], in which the fatty acid metal salt is a metal salt of capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, montanic acid, or melissic acid.
  • the fatty acid metal salt is a metal salt of capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, montanic acid, or melissic acid.
  • the present disclosure relates to a masterbatch according to any one of [1] to [5], wherein the heteroatom-containing ligand is one or more amine ligands selected from picolinic acid, 2- ⁇ [(2-dimethylamino)ethyl]methylamino ⁇ ethanol, 1,2-propanediamine, 1,2-cyclohexanediamine, monoethanolamine, diethanolamine, triethanolamine, imidazole, 1-methylimidazole, 2-methylimidazole, 4-methylimidazole, 2,4-dimethylimidazole, 1,4-diethylimidazole, 8-quinolinol, 5-chloro-8-quinolinol, 2,2'-bipyridyl and its derivatives, and 2,2'-[propane-1,2-diylbis(azanylylidenemethanylylidene)]diphenol and its derivatives.
  • the heteroatom-containing ligand is one or more amine ligands selected from picolin
  • the present disclosure provides a method for producing a masterbatch, comprising a step of blending and melt-kneading a thermoplastic resin and an antibacterial and antiviral agent, blending an antibacterial and antiviral agent in an amount within the range of 0.03 to 90 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the masterbatch, or blending an antibacterial and antiviral agent such that the content of metal derived from the antibacterial and antiviral agent is within the range of 0.0015 to 45 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the masterbatch;
  • the present invention relates to a method for producing a master batch, wherein the antibacterial and antiviral agent is one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and
  • the present disclosure also provides a method for producing a masterbatch, the method comprising the steps of blending and melt-kneading a thermoplastic resin and an antibacterial and antiviral agent, the content of the antibacterial and antiviral agent is in the range of 0.03 to 90 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the masterbatch;
  • the antibacterial and antiviral agent may be one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and a fatty acid metal salt, and the metals in the fatty acid metal salt, the metal complex of a heteroatom-containing compound ligand and a metal ion, and the metal complex of a heteroatom-containing compound ligand and a fatty acid metal salt may each independently be a lanthanoid, bismuth, manganese, magnesium
  • the present disclosure also provides a method for producing a masterbatch, the method comprising the steps of blending and melt-kneading a thermoplastic resin and an antibacterial and antiviral agent, the antibacterial and antiviral agent is blended so that the content of the metal derived from the antibacterial and antiviral agent falls within the range of 0.0015 to 45 parts by mass per 100 parts by mass in total of the thermoplastic resin and the antibacterial and antiviral agent in the masterbatch;
  • the antibacterial and antiviral agent may be one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and a fatty acid metal salt, and the metals in the fatty acid metal salt, the metal complex of a heteroatom-containing compound ligand and a metal ion, and the metal complex of a heteroatom-containing compound ligand and a fatty acid metal salt may each independently be
  • the present disclosure provides a thermoplastic resin composition containing a thermoplastic resin and an antibacterial and antiviral agent,
  • the antibacterial and antiviral agent is contained in an amount of 0.01 to 30 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition, or the antibacterial and antiviral agent is contained so that the content of metal derived from the antibacterial and antiviral agent is in the range of 0.0005 to 15 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition;
  • the present invention relates to a thermoplastic resin composition, characterized in that the antibacterial and antiviral agent is one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and a fatty acid metal salt, and the metals in the fatty acid metal salt, the
  • the present disclosure provides a thermoplastic resin composition
  • a thermoplastic resin composition comprising a thermoplastic resin and an antibacterial and antiviral agent
  • the antibacterial and antiviral agent is contained in an amount of 0.01 to 30 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition;
  • the antibacterial and antiviral agent may be one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and a fatty acid metal salt, and the metals in the fatty acid metal salt, the metal complex of a heteroatom-containing compound ligand and a metal ion, and the metal complex of a heteroatom-containing compound ligand and a fatty acid metal salt may each independently be a lanthanoid, bismuth, manganese, magnesium, lead, yttrium, cobalt, or
  • the present disclosure also provides a thermoplastic resin composition
  • a thermoplastic resin composition comprising a thermoplastic resin and an antibacterial and antiviral agent, the content of the metal derived from the antibacterial and antiviral agent is in the range of 0.0005 to 15 parts by mass per 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition;
  • the antibacterial and antiviral agent may be one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and a fatty acid metal salt, and the metals in the fatty acid metal salt, the metal complex of a heteroatom-containing compound ligand and a metal ion, and the metal complex of a heteroatom-containing compound ligand and a fatty acid metal salt may each independently be a lanthanoid, bismuth, manganese, magnesium, lead, yttrium,
  • the present disclosure also provides a method for producing a thermoplastic resin composition, comprising the steps of blending a thermoplastic resin as a diluting resin with the masterbatch according to any one of [1] to [5] above, and melt-kneading the blend,
  • the present invention relates to a method for producing a thermoplastic resin composition, characterized in that a master batch and a diluent resin are blended together so that the antibacterial and antiviral agent is in the range of 0.01 to 30 parts by mass per 100 parts by mass of the thermoplastic resin, antibacterial and antiviral agent, and diluent resin in the master batch, or the master batch and a diluent resin are blended together so that the content of metal derived from the antibacterial and antiviral agent is in the range of 0.0005 to 15 parts by mass per 100 parts by mass of the thermoplastic resin, antibacterial and antiviral agent, and diluent resin in the master batch.
  • the present disclosure also provides a method for producing a thermoplastic resin composition, comprising the steps of blending a thermoplastic resin as a diluting resin with the masterbatch according to any one of [1] to [5] above, and melt-kneading the blend,
  • the master batch and a diluent resin may be blended so that the antibacterial and antiviral agent is in the range of 0.01 to 30 parts by mass per 100 parts by mass in total of the thermoplastic resin and the antibacterial and antiviral agent in the master batch, and the diluent resin.
  • the present disclosure also provides a method for producing a thermoplastic resin composition, comprising the steps of blending a thermoplastic resin as a diluting resin with the masterbatch according to any one of [1] to [5] above, and melt-kneading the blend,
  • the master batch and a diluent resin may be blended so that the content of the metal derived from the antibacterial and antiviral agent is in the range of 0.0005 to 15 parts by mass per 100 parts by mass in total of the thermoplastic resin and the antibacterial and antiviral agent in the master batch, and the diluent resin.
  • the present disclosure also provides a method for producing a thermoplastic resin composition, comprising a step of blending and melt-kneading a thermoplastic resin and an antibacterial and antiviral agent, blending an antibacterial and antiviral agent in an amount within the range of 0.01 to 30 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition, or blending a thermoplastic resin and an antibacterial and antiviral agent such that the content of metal derived from the antibacterial and antiviral agent is within the range of 0.0005 to 15 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition;
  • the present invention relates to a method for producing a thermoplastic resin composition, wherein the antibacterial and antiviral agent is one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex
  • the present disclosure also provides a method for producing a thermoplastic resin composition, the method comprising a step of blending and melt-kneading a thermoplastic resin and an antibacterial and antiviral agent, blending the antibacterial and antiviral agent in an amount of 0.01 to 30 parts by mass per 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition;
  • the antibacterial and antiviral agent may be one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and a fatty acid metal salt, and the metals in the fatty acid metal salt, the metal complex of a heteroatom-containing compound ligand and a metal ion, and the metal complex of a heteroatom-containing compound ligand and a fatty acid metal salt may each independently be a lanthanoid, bismuth, manganese, magnesium, lead
  • the present disclosure also provides a method for producing a thermoplastic resin composition, the method comprising a step of blending and melt-kneading a thermoplastic resin and an antibacterial and antiviral agent, blending a thermoplastic resin and an antibacterial and antiviral agent so that the content of a metal derived from the antibacterial and antiviral agent is in the range of 0.0005 to 15 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition;
  • the antibacterial and antiviral agent may be one or more selected from the group consisting of a fatty acid metal salt, a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and a fatty acid metal salt, and the metals in the fatty acid metal salt, the metal complex of a heteroatom-containing compound ligand and a metal ion, and the metal complex of a heteroatom-containing compound ligand and
  • the present disclosure relates to a molded article obtained by molding the thermoplastic resin composition described in [7] above.
  • the present disclosure relates to a method for producing a molded article, comprising a step of melt-molding the resin composition described in [7] above.
  • thermoplastic resin composition capable of providing the molded article and having excellent processability
  • a masterbatch capable of providing the thermoplastic resin composition, and a method for producing the same.
  • thermoplastic resin used in the present disclosure is not particularly limited as long as it does not impair the effects of the present disclosure, and examples thereof include polyolefin resins, polycarbonate resins, polystyrene resins, acrylic resins, polyoxymethylene resins, polyester resins, vinyl chloride resins, cycloolefin polymers (COP), and thermoplastic elastomers.
  • the thermoplastic resin used in the present disclosure may be one type or a mixture of two or more types. When two or more types are mixed, it is preferable to use a combination of resins with high compatibility.
  • the polyolefin resin is a polyolefin resin obtained by polymerizing at least one kind of olefin, and may be a homopolymer or a copolymer.
  • olefins include ⁇ -olefins having 4 to 12 carbon atoms, including ethylene, propylene, isobutylene, and isobutene (1-butene), butadiene, isoprene, (meth)acrylic acid esters, (meth)acrylic acid, (meth)acrylamide, vinyl alcohol, vinyl acetate, vinyl chloride, styrene, and acrylonitrile.
  • Examples of ⁇ -olefins having 4 to 12 carbon atoms include 1-butene, 2-methyl-1-propene, 2-methyl-1-butene, 3-methyl-1-butene, 1-hexene, 2-ethyl-1-butene, 2,3-dimethyl-1-butene, 2-methyl-1-pentene, 3-methyl-1-pentene, 4-methyl-1-pentene, 3,3-dimethyl-1-butene, 1-heptene, methyl-1-hexene, dimethyl
  • These include 1-pentene, ethyl-1-pentene, trimethyl-1-butene, methylethyl-1-butene, 1-octene, methyl-1-pentene, ethyl-1-hexene, dimethyl-1-hexene, propyl-1-heptene, methylethyl-1-heptene, trimethyl-1-pentene, propyl-1-pentene, diethyl-1-butene
  • Polyolefin resins are not particularly limited, but examples include polyethylene resins, polypropylene resins, polymethylpentene resins, polyisobutylene resins, polyisobutene resins, polyisoprene resins, polybutadiene resins, etc. Of these resins, polyethylene resins, polypropylene resins, and polymethylpentene resins are preferred.
  • examples include high density polyethylene (HDPE), low density polyethylene (LDPE), very low density polyethylene (VLDPE), linear low density polyethylene (LLDPE), and ultra-high molecular weight polyethylene (UHMW-PE), of which high density polyethylene, linear low density polyethylene, and low density polyethylene are preferred.
  • HDPE high density polyethylene
  • LDPE low density polyethylene
  • VLDPE very low density polyethylene
  • LLDPE linear low density polyethylene
  • UHMW-PE ultra-high molecular weight polyethylene
  • Polycarbonate resins include polycarbonate (PC), etc.
  • Polystyrene resins include polystyrene (PS), imide-modified polystyrene, acrylonitrile-butadiene-styrene (ABS) resin, imide-modified ABS resin, styrene-acrylonitrile copolymer (SAN) resin, acrylonitrile-ethylene-propylene-diene-styrene (AES) resin, etc.
  • Acrylic resins include polyacrylic acid, polymethacrylic acid, polymethyl acrylate, polymethyl methacrylate (PMMA), polyethyl methacrylate, etc.
  • Polyoxymethylene resins include polyoxymethylene (POM), etc.
  • Polyester resins include aromatic polyester resins such as polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polytrimethylene terephthalate (PTT), polyethylene naphthalate (PEN), and polybutylene naphthalate.
  • Vinyl chloride resins include polyvinyl chloride (PVC), vinyl chloride-vinyl acetate copolymer resin, etc.
  • Thermoplastic elastomers include polyurethane thermoplastic elastomers, polyester thermoplastic elastomers, styrene thermoplastic elastomers, olefin thermoplastic elastomers, etc.
  • the antibacterial and antiviral agent used in the present disclosure is one or more selected from the group consisting of fatty acid metal salts, metal complexes of heteroatom-containing ligands and metal ions, and metal complexes of heteroatom-containing ligands and fatty acid metal salts, wherein the metals in the fatty acid metal salts, the metal complexes of heteroatom-containing compound ligands and metal ions, and the metal complexes of heteroatom-containing compound ligands and fatty acid metal salts are each independently a lanthanoid, bismuth, manganese, magnesium, lead, yttrium, cobalt, or copper.
  • the antibacterial and antiviral agent used in this disclosure takes the form of a fatty acid metal salt or metal complex, and due to the antibacterial and antiviral properties of the metal and the high compatibility of the fatty acid or complex ligand with organic matter, when blended with a thermoplastic resin, it is believed to impart antibacterial and antiviral properties to the resulting thermoplastic resin composition while reducing the impact on appearance, such as the loss of transparency caused by the antibacterial and antiviral agent.
  • antibacterial means the effect of reducing the number of bacteria, the effect of suppressing the increase in the number of bacteria, etc.
  • antiviral means the effect of reducing the number of viruses, the effect of inactivating viruses, the effect of reducing the infectivity of viruses, etc.
  • antibacterial and antiviral agent means a substance that exerts both “antibacterial” and “antiviral” effects.
  • the bacteria to be treated with antibacterial agents are not particularly limited, and may be either bacteria or fungi.
  • bacteria include gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, Salmonella, Moraxella, and Legionella; and gram-positive bacteria such as Staphylococcus aureus and Clostridium bacteria.
  • fungi include yeasts such as Candida, Rhodotorula, and baker's yeast; and molds such as red mold and black mold.
  • viruses that are the subject of antiviral treatment are not particularly limited, and may be any of the known enveloped viruses (viruses that have an envelope) and non-enveloped viruses (viruses that do not have an envelope).
  • enveloped viruses examples include coronavirus, influenza virus, rubella virus, Ebola virus, measles virus, chickenpox/shingles virus, herpes virus, mumps virus, arbovirus, respiratory syncytial virus, SARS virus, hepatitis virus (e.g., hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, etc.), yellow fever virus, AIDS virus, rabies virus, hantavirus, dengue virus, Nipah virus, lyssavirus, etc.
  • coronavirus e.g., hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, etc.
  • non-enveloped viruses examples include adenovirus, norovirus, rotavirus, human papillomavirus, poliovirus, enterovirus, coxsackievirus, human parvovirus, encephalomyocarditis virus, polyomavirus, BK virus, rhinovirus, and feline calicivirus.
  • antibacterial and antiviral agents used in this disclosure are described below.
  • the antibacterial and antiviral agent used in the present disclosure may be a fatty acid metal salt.
  • the fatty acid metal salt is a metal salt of a fatty acid, and the metals constituting the metal salt may each independently be lanthanoid, bismuth, manganese, magnesium, lead, yttrium, cobalt, or copper.
  • lanthanoid is an element belonging to group 3A of the periodic table, and is a general term for 15 elements with atomic numbers 57 to 71, that is, lanthanum to lutetium.
  • lanthanoids, bismuth, and magnesium are preferred from the viewpoint of making it difficult for coloration to occur due to the addition of an antibacterial and antiviral agent.
  • the lanthanoids lanthanum, praseodymium, neodymium, samarium, and gadolinium are particularly preferred.
  • the fatty acid is a fatty acid having 2 to 31 carbon atoms.
  • the fatty acid may also include a linear, branched, or alicyclic structure.
  • Fatty acids having 2 to 31 carbon atoms have a carboxy group (COOH) and a fatty acid residue (carboxylic acid residue) having 1 to 30 carbon atoms.
  • fatty acids include fatty acids such as saturated fatty acids and unsaturated fatty acids.
  • saturated fatty acids include saturated fatty acids with a straight chain structure such as acetic acid, propionic acid, butanoic acid, pentanoic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, montanic acid, and melissic acid, and saturated fatty acids with a branched or alicyclic structure such as octylic acid (2-ethylhexanoic acid), neodecanoic acid, isostearic acid, naphthenic acid, and isononanoic acid.
  • saturated fatty acids with a straight chain structure such as acetic acid, propionic acid, butanoic acid, pentanoic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid
  • unsaturated fatty acids include monounsaturated fatty acids such as acrylic acid, methacrylic acid, palmitoleic acid, oleic acid, elaidic acid, paccenic acid, and erucic acid, and polyunsaturated fatty acids derived from vegetable oils such as tung oil acid, tall oil fatty acid, coconut oil fatty acid, soybean oil fatty acid, linseed oil fatty acid, safflower oil fatty acid, dehydrated castor oil fatty acid, and tung oil fatty acid.
  • monounsaturated fatty acids such as acrylic acid, methacrylic acid, palmitoleic acid, oleic acid, elaidic acid, paccenic acid, and erucic acid
  • polyunsaturated fatty acids derived from vegetable oils such as tung oil acid, tall oil fatty acid, coconut oil fatty acid, soybean oil fatty acid, linseed oil fatty acid, safflower oil fatty acid, dehydrated castor oil
  • fatty acids having 2 to 31 carbon atoms are more preferred, and most preferred are capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, montanic acid, melissic acid, etc.
  • the fatty acid metal salt used as the antibacterial and antiviral agent in the present disclosure is preferably, for example, a compound represented by the following general formula (1):
  • R 1 is a hydrogen atom or a hydrocarbon group having 1 to 30 carbon atoms; n1 is an integer ranging from 1 to 4; M1 is a lanthanide, bismuth, manganese, magnesium, lead, yttrium, cobalt or copper.
  • n1 is an integer of 2 or more
  • multiple R 1s may be the same or different.
  • the hydrocarbon group having 1 to 30 carbon atoms for R 1 may be a straight-chain hydrocarbon group, a branched hydrocarbon group, or may contain an alicyclic structure.
  • the hydrocarbon group having 1 to 30 carbon atoms represented by R1 corresponds to a fatty acid residue (carboxylic acid residue) obtained by removing a carboxy group (COOH) from a carboxylic acid having 2 to 31 carbon atoms represented by R1COOH used in the production of a fatty acid metal salt.
  • examples of the fatty acid residue (carboxylic acid residue) include residues obtained by removing a carboxy group from the fatty acids listed above.
  • the hydrocarbon group having 1 to 30 carbon atoms for R1 is preferably an alkyl group having 10 to 30 carbon atoms, more preferably a capric acid residue, a lauric acid residue, a myristic acid residue, a palmitic acid residue, a stearic acid residue, an arachidic acid residue, a behenic acid residue, a lignoceric acid residue, a cerotic acid residue, a montanic acid residue, a melissic acid residue, or the like, from the viewpoint of ease of handling the compound and of suppressing thermal degradation when the thermoplastic resin composition is processed into a master batch or pellets.
  • M1 is a lanthanide, bismuth, manganese, magnesium, lead, yttrium, cobalt or copper.
  • n1 is a numerical value determined by the ionic valence of the metal atom of M1 . For example, if M1 is neodymium, n1 is 3, and if M1 is cobalt, n1 is 2.
  • the fatty acid metal salt which is the antibacterial and antiviral agent of the present disclosure, may also be in the form of a fatty acid metal borate.
  • a fatty acid metal borate is a compound represented by the following general formula (2).
  • R2 is a hydrogen atom or a hydrocarbon group having 1 to 30 carbon atoms
  • M2 is a lanthanide, bismuth, manganese, magnesium, lead, yttrium, cobalt or copper.
  • the hydrocarbon group having 1 to 30 carbon atoms for R2 is the same as the hydrocarbon group having 1 to 30 carbon atoms for R1 in the general formula (1).
  • the metal for M2 is the same as the metal for M1 in the general formula (1).
  • a fatty acid metal salt is used as the antibacterial and antiviral agent used in this disclosure, a single type of fatty acid metal salt may be used, or two or more types of fatty acid metal salts having different structures may be used.
  • Fatty acid metal salts can be produced by known methods, and commercially available products may also be used.
  • the antibacterial and antiviral agent used in the present disclosure may be a metal complex of a heteroatom-containing ligand and a metal ion, and a metal complex of a heteroatom-containing ligand and a fatty acid metal salt, which may be a compound in which a metal ion or a fatty acid metal salt and a heteroatom-containing ligand form a complex via a coordinate bond.
  • the same metal ion as the metal of the fatty acid metal salt explained as the antibacterial and antiviral agent used in the present disclosure can be used.
  • the fatty acid metal salt in which the heteroatom-containing ligand forms a metal complex the same fatty acid metal salts described as the antibacterial and antiviral agent used in the present disclosure can be used.
  • the heteroatom-containing ligand that forms the metal complex may be a ligand that has one or more heteroatoms selected from the group consisting of nitrogen, oxygen, sulfur, and phosphorus in the molecule.
  • the heteroatom-containing ligand include N-methylmorpholine, pyridine, 1,8-diazabicyclo[5.4.0]undecene-7 (DBU), 1,5-diazabicyclo[4.3.0]nonene-5 (DBN), 1,4-diazabicyclo[2.2.2]octane (DABCO), 4-dimethylaminoamine (DMAP), dicyandiamide (DICY), tri-n-butylamine, dimethylbenzylamine, butylamine, 1,2-propanediamine, 1,2-cyclohexanediamine, octylamine, monoethanolamine, diethanolamine, triethanolamine, dimethylbenzylamine, butylamine, 1,2-propanediamine, 1,2-cyclohexanediamine, octy
  • amine 2-[[(2-dimethylamino)ethyl]methylamino]ethanol, picolinic acid, 2,2'-[propane-1,2-diylbis(azanylylidenemethanylylidene)]diphenol, imidazole, 1-methylimidazole, 2-methylimidazole, 4-methylimidazole, 2,4-dimethylimidazole, 1,4-diethylimidazole, 3-aminopropyltrimethoxysilane, 3-aminopropyltriethoxysilane, 3-(N-phenyl)aminopropyltrimethoxysilane, 3-(2-aminoethyl)aminopropyltrimethoxysilane, 3 amine compounds such as -(2-aminoethyl)aminopropylmethyldimethoxysilane, tetramethylammonium hydroxide, 8-quinolinol, 5-chloro-8-quino
  • the heteroatom-containing ligand is preferably one or more amine ligands selected from picolinic acid, 2- ⁇ [(2-dimethylamino)ethyl]methylamino ⁇ ethanol, 1,2-propanediamine, 1,2-cyclohexanediamine, monoethanolamine, diethanolamine, triethanolamine, imidazole, 1-methylimidazole, 2-methylimidazole, 4-methylimidazole, 2,4-dimethylimidazole, 1,4-diethylimidazole, 8-quinolinol, 5-chloro-8-quinolinol, 2,2'-bipyridyl and its derivatives, and 2,2'-[propane-1,2-diylbis(azanylylidenemethanylylidene)]diphenol and its derivatives.
  • picolinic acid 2- ⁇ [(2-dimethylamino)ethyl]methylamino ⁇ ethanol, 1,2-propanediamine, 1,2-cyclohexanediamine,
  • the heteroatom-containing ligand that forms the metal complex may be of one type alone or of two or more types that are different in structure.
  • the ratio (molar ratio) of the metal ion or fatty acid metal salt to the heteroatom-containing ligand is, for example, in the range of 0.1 to 12 moles of the heteroatom-containing ligand per mole of metal atom of the metal ion or fatty acid metal salt, preferably in the range of 0.3 to 10 moles, and more preferably in the range of 0.5 to 10 moles.
  • the melting points of the fatty acid metal salt, the metal complex of the heteroatom-containing compound ligand and metal ion, and the metal complex of the heteroatom-containing compound ligand and fatty acid metal salt contained in the antibacterial and antiviral agent used in the present disclosure are not particularly limited, but from the viewpoint of the ease of handling of the compounds and the suppression of thermal degradation when processed into a master batch or a pellet of a thermoplastic resin composition, it is preferable that the compounds are solid in the working environment (0°C to 45°C), and more preferably have a melting point of 50°C or higher, even more preferably 60°C or higher, and particularly preferably 70°C or higher.
  • the upper limit is not particularly limited, but may be 250°C or lower.
  • the content of the metal derived from the fatty acid metal salt, the metal complex of the heteroatom-containing compound ligand and a metal ion, and the metal complex of the heteroatom-containing compound ligand and a fatty acid metal salt (hereinafter sometimes referred to as "metal derived from the antibacterial and antiviral agent" or simply “metal") contained in the antibacterial and antiviral agent used in the present disclosure is not particularly limited, but is preferably 5 parts by mass or more, more preferably 7.5 parts by mass or more, and particularly preferably 10 parts by mass or more, relative to 100 parts by mass of the antibacterial and antiviral agent. Also, it is preferably 50 parts by mass or less, more preferably 40 parts by mass or less, and even more preferably 30 parts by mass or less.
  • the antibacterial and antiviral agent used in the present disclosure is preferably a water-insoluble antibacterial and antiviral agent.
  • the water-insoluble antibacterial and antiviral agent has excellent durability of antibacterial and antiviral properties even when exposed to water such as rain.
  • water-insoluble means that the amount of water required to dissolve 1 g of the antibacterial and antiviral agent at 20°C is 10 ml or more.
  • the antibacterial and antiviral agents that is, the metal complex of a heteroatom-containing ligand and a metal ion and the metal complex of a heteroatom-containing ligand and a fatty acid metal salt, can be produced by known methods, and can be produced by reacting a metal alone or a fatty acid metal salt with a heteroatom-containing ligand.
  • the metal complex may be a commercially available product.
  • the masterbatch of the present disclosure contains a thermoplastic resin and an antibacterial and antiviral agent.
  • the masterbatch of the present disclosure contains an antibacterial, antiviral agent in a range of 0.03 to 90 parts by mass per 100 parts by mass of the thermoplastic resin and the antibacterial, antiviral agent in the masterbatch, or contains the antibacterial, antiviral agent such that the content of metal derived from the antibacterial, antiviral agent is in the range of 0.0015 to 45 parts by mass per 100 parts by mass of the thermoplastic resin and the antibacterial, antiviral agent in the masterbatch.
  • the composition ratio of the thermoplastic resin and the antibacterial and antiviral agent contained in the masterbatch of the present disclosure is preferably 0.03 parts by mass or more, more preferably 0.15 parts by mass or more, and even more preferably 0.3 parts by mass or more per 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent in the masterbatch in order to impart excellent dispersibility and antiviral properties to the molded article obtained via the masterbatch, but is preferably in the range of 90 parts by mass or less, more preferably 75 parts by mass or less, and even more preferably 60 parts by mass or less, taking into consideration the suppression of thermal degradation during processing into the masterbatch and the cost benefits during transportation.
  • the content of the metal derived from the antibacterial and antiviral agent contained in the master batch of the present disclosure is not particularly limited, but can be calculated taking into consideration the content of the metal contained in the antibacterial and antiviral agent and the composition ratio of the antibacterial and antiviral agent contained in the master batch. That is, the content of the metal is preferably 0.0015 parts by mass or more, more preferably 0.0075 parts by mass or more, and even more preferably 0.015 parts by mass or more, and preferably 45 parts by mass or less, more preferably 37.5 parts by mass or less, and even more preferably 30 parts by mass or less, relative to a total of 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent contained in the master batch. If the content of the metal contained in the master batch is within the above range, the molded body obtained via the master batch can be imparted with excellent dispersibility, transparency, and antibacterial and antiviral properties.
  • the master batch of the present disclosure may also contain various known additives as optional components within a range that does not impair the effects of the present disclosure.
  • optional additives include antiblocking agents such as silica, flame retardants such as halogen-based flame retardants, nitrogen-based flame retardants, phosphate ester-based flame retardants, inorganic flame retardants such as metal hydroxides and oxides, and silicone-based flame retardants, antioxidants such as hindered phenol compounds, hydroquinone compounds, phosphite compounds, and their substitutes, weather resistance agents such as resorcinol compounds, salicylate compounds, benzotriazole compounds, benzophenone compounds, and hindered amine compounds, release agents or lubricants such as aliphatic alcohols, aliphatic amides, aliphatic bisamides, bisurea compounds, and polyethylene wax, pigments such as phthalocyanine and carbon black, dyes such as nigros
  • antistatic agents include crystal nucleating agents such as octyl p-oxybenzoate and N-butylbenzenesulfonamide, plasticizers such as octyl p-oxybenzoate and N-butylbenzenesulfonamide, antistatic agents such as alkyl sulfate-type anionic antistatic agents, quaternary ammonium salt-type cationic antistatic agents, nonionic antistatic agents such as polyoxyethylene sorbitan monostearate, and betaine-type amphoteric antistatic agents, as well as various particulate, needle-like, and plate-like fillers such as graphite, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, antimony oxide, aluminum oxide, zinc oxide, iron oxide, zinc sulfide, zinc, lead, nickel, aluminum, iron, stainless steel, bentonite, montmorillonite, and synthetic mica, and reinforcing materials such as glass fiber, glass flakes
  • composition ratio is not particularly limited as long as it does not impair the effects of the present disclosure, but the desired function can be freely adjusted by adjusting the type and amount of these additives, preferably within the range of 0.01 parts by mass or more and 300 parts by mass or less per 100 parts by mass of the thermoplastic resin and antibacterial and antiviral agent in the master batch.
  • the method for producing a masterbatch according to the present disclosure includes a step of blending a thermoplastic resin and an antibacterial and antiviral agent as essential components, and melt-kneading the blend.
  • the method for producing a masterbatch disclosed herein involves blending an antibacterial and antiviral agent in the range of 0.03 to 90 parts by mass per 100 parts by mass of the thermoplastic resin and antibacterial and antiviral agent in the masterbatch, or blending the antibacterial and antiviral agent so that the content of metal derived from the antibacterial and antiviral agent is in the range of 0.0015 to 45 parts by mass per 100 parts by mass of the thermoplastic resin and antibacterial and antiviral agent in the masterbatch.
  • the compounding ratio may be, for example, adjusted and compounded so that the antibacterial and antiviral agent is preferably 0.03 parts by mass or more, more preferably 0.15 parts by mass or more, and even more preferably 0.3 parts by mass or more, and preferably 90 parts by mass or less, more preferably 75 parts by mass or less, and even more preferably 60 parts by mass or less, per 100 parts by mass of the total of the thermoplastic resin and antibacterial and antiviral agent in the masterbatch.
  • the amount of metal contained in the master batch of the present disclosure is not particularly limited, but the antibacterial and antiviral agent can be blended in consideration of the amount of metal contained in the antibacterial and antiviral agent and the composition ratio of the antibacterial and antiviral agent contained in the master batch.
  • thermoplastic resin and the antibacterial and antiviral agent may be blended in such a way that the amount of metal contained in the master batch is preferably 0.0015 parts by mass or more, more preferably 0.0075 parts by mass or more, and even more preferably 0.015 parts by mass or more, and preferably 45 parts by mass or less, more preferably 37.5 parts by mass or less, and even more preferably 30 parts by mass or less, per 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent contained in the master batch in total.
  • the above-mentioned components are premixed as necessary using a mixer such as a V-type blender, ribbon blender, or Henschel mixer, and then melt-kneaded using a known mixer such as a single-screw extrusion type kneader, open roll mixer, pressure kneader, Banbury mixer, or twin-screw extrusion type kneader, with the resin set temperature set to above the melting point.
  • twin-screw extrusion type kneaders are preferred in terms of kneading ability and productivity.
  • the mixture is processed into pellets or the like according to conventional methods to obtain the master batch of the present disclosure.
  • thermoplastic resin composition contains a thermoplastic resin and an antibacterial and antiviral agent.
  • the thermoplastic resin composition of the present disclosure contains an antibacterial and antiviral agent in a range of 0.01 to 30 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent, or contains the antibacterial and antiviral agent such that the content of metal derived from the antibacterial and antiviral agent is in the range of 0.0005 to 15 parts by mass per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition.
  • the composition ratio of the thermoplastic resin and the antibacterial and antiviral agent contained in the thermoplastic resin composition of the present disclosure is preferably in the range of 0.01 parts by mass or more, more preferably 0.05 parts by mass or more, and even more preferably 0.1 parts by mass or more, to preferably 30 parts by mass or less, more preferably 25 parts by mass or less, and even more preferably 20 parts by mass or less, per 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition in total, from the viewpoint of imparting excellent dispersibility and antiviral properties to a molded article obtained using the thermoplastic resin composition of the present disclosure.
  • the content of the metal derived from the antibacterial and antiviral agent contained in the thermoplastic resin composition of the present disclosure is not particularly limited, but can be calculated taking into consideration the content of the metal contained in the antibacterial and antiviral agent and the composition ratio of the antibacterial and antiviral agent contained in the thermoplastic resin composition. That is, the content of the metal is preferably 0.0005 parts by mass or more, more preferably 0.0025 parts by mass or more, and even more preferably 0.005 parts by mass or more, and preferably 15 parts by mass or less, more preferably 12.5 parts by mass or less, and even more preferably 10 parts by mass or less, relative to 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent contained in the thermoplastic resin composition. If the content of the metal contained in the thermoplastic resin composition is within the above range, the finally obtained molded body can be imparted with excellent dispersibility, transparency, and antibacterial and antiviral properties.
  • the method for producing a thermoplastic resin composition includes a step of blending a thermoplastic resin for dilution (hereinafter sometimes referred to as a "dilution resin") with the masterbatch and melt-kneading the blend.
  • a thermoplastic resin for dilution hereinafter sometimes referred to as a "dilution resin”
  • melt-kneading the blend.
  • thermoplastic resin in the master batch and the thermoplastic resin in the diluent resin used in this disclosure may be the same type of resin or different types of resin depending on the purpose, but it is preferable to use the same type of resin from the standpoint of compatibility.
  • the manufacturing method of the thermoplastic resin composition disclosed herein involves blending an antibacterial and antiviral agent in an amount ranging from 0.01 to 30 parts by mass per 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent combined, or blending an antibacterial and antiviral agent such that the content of metal derived from the antibacterial and antiviral agent is in the range of 0.0005 to 15 parts by mass per 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent combined in the thermoplastic resin composition.
  • the blending ratio may be, for example, such that the masterbatch of the present disclosure and the diluent resin are prepared and blended such that the antibacterial and antiviral agent is preferably 0.01 parts by mass or more, more preferably 0.05 parts by mass or more, and even more preferably 0.1 parts by mass or more, and preferably 30 parts by mass or less, more preferably 25 parts by mass or less, and even more preferably 20 parts by mass or less, per 100 parts by mass of the total of the thermoplastic resin and antibacterial and antiviral agent in the masterbatch, and the diluent resin.
  • the content of the metal contained in the thermoplastic resin composition of the present disclosure is not particularly limited, but the master batch and the diluent resin may be blended in consideration of the content of the metal contained in the antibacterial and antiviral agent and the composition ratio of the antibacterial and antiviral agent contained in the thermoplastic resin composition.
  • the master batch and the diluent resin may be blended in such a way that the content of the metal is preferably 0.0005 parts by mass or more, more preferably 0.0025 parts by mass or more, and even more preferably 0.005 parts by mass or more, and preferably 15 parts by mass or less, more preferably 12.5 parts by mass or less, and even more preferably 10 parts by mass or less, per 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the master batch, and the diluent resin.
  • thermoplastic resin composition of the present disclosure is preferably produced by blending and melt-kneading the master batch of the present disclosure with a diluent resin as described above, since this allows the antibacterial and antiviral agent to be stably and uniformly dispersed, can be added at high concentrations, and provides the molded article with excellent transparency and surface appearance, but it can also be produced without using a master batch.
  • the method for producing the thermoplastic resin composition of the present disclosure includes a step of blending and melt-kneading a thermoplastic resin and an antibacterial and antiviral agent as raw materials so that they have a predetermined composition ratio.
  • the blending ratio is, for example, preferably 0.01 parts by mass or more, more preferably 0.05 parts by mass or more, and even more preferably 0.1 parts by mass or more, and preferably 30 parts by mass or less, more preferably 25 parts by mass or less, and even more preferably 20 parts by mass or less, relative to a total of 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition.
  • the thermoplastic resin and the antibacterial and antiviral agent can also be blended in consideration of the content of metal contained in the antibacterial and antiviral agent and the composition ratio of the antibacterial and antiviral agent contained in the thermoplastic resin composition.
  • thermoplastic resin and the antibacterial and antiviral agent may be blended so that the content of the metal is preferably in the range of 0.0005 parts by mass or more, more preferably 0.0025 parts by mass or more, and even more preferably 0.005 parts by mass or more, and preferably 15 parts by mass or less, more preferably 12.5 parts by mass or less, and even more preferably 10 parts by mass or less, relative to 100 parts by mass of the total of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition.
  • the melt-kneading method is not particularly limited, and for example, a method similar to the method for producing the master batch can be adopted.
  • the thermoplastic resin composition obtained by melt-kneading can then be temporarily processed into pellets or the like according to a conventional method.
  • thermoplastic resin composition of the present disclosure may also contain various known additives as optional components within a range that does not impair the effects of the present disclosure.
  • various additives that can be added as optional components include the same additives that can be added to the above-mentioned master batch. Of these, from the viewpoint of blocking inhibition, it is preferable to further add an antiblocking agent such as silica.
  • composition ratio is not particularly limited as long as it does not impair the effects of the present disclosure, but the desired function can be freely adjusted by adjusting the type and amount of these additives, preferably in the range of 0.01 parts by mass or more to 300 parts by mass or less per 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition.
  • an antiblocking agent is further added, it is preferably added in the range of 0.01 parts by mass or more to 3 parts by mass or less per 100 parts by mass of the thermoplastic resin and the antibacterial and antiviral agent in the thermoplastic resin composition.
  • the molded article of the present disclosure has extremely excellent antiviral and antibacterial properties, and can be used in applications where these activities are required. For this reason, the molded article of the present disclosure can be suitably used for applications such as films, sheets, fibers, and tubes, and can be laminated to form a multilayer film or sheet by laminating multiple films or sheets, or can be made into a fabric with woven fibers.
  • known molding methods such as injection molding, compression molding, extrusion molding, pultrusion molding, blow molding, and transfer molding can also be applied.
  • a molding material based on the resin composition of the present disclosure can be melted at a high temperature equal to or higher than the melting temperature of the resin, and the molten molding material can be extruded from a nozzle in the head to form a shape, which can then be stacked in multiple layers to form a three-dimensional object.
  • the fabric may be in any form, such as woven fabric, knitted fabric, nonwoven fabric, etc. If necessary, the fabric may be colored with disperse dyes, acid dyes, direct dyes, reactive dyes, pigments, etc.
  • the fabric of the present disclosure can be used in a variety of textile products, such as clothing for general use, innerwear, sports, medical use, etc., bedding materials such as duvet covers and sheets, interior goods such as curtains, carpets, chairs, cushion covers, wallpaper, etc., industrial materials such as tent sheets, flags, curtains, etc., sheet materials for transportation vehicles such as automobiles, aircraft, and railway cars, sanitary materials, textile materials for air treatment, textile materials for water treatment, etc.
  • the molded articles can be processed and used in products that are easily touched by human hands, such as food packaging containers, bathtubs, building fixtures, and housings for cash registers, computers, and smartphones, but they can also be used for medical purposes, such as stents, coil obturators, catheter tubes, syringes (needles and bodies), shunt tubes, drain tubes, and implant medical devices.
  • medical purposes such as stents, coil obturators, catheter tubes, syringes (needles and bodies), shunt tubes, drain tubes, and implant medical devices.
  • the diameter (number average fiber diameter) of the fiber obtained by melt spinning the resin composition of the present disclosure varies depending on the application, and can be any diameter. However, since the smaller the fiber diameter, the better the antiviral activity, it is preferably 100 ⁇ m or less, more preferably 40 ⁇ m or less, even more preferably 20 ⁇ m or less, and particularly preferably 10 ⁇ m or less.
  • the lower limit is not limited, but is preferably 0.01 ⁇ m or more, more preferably 0.1 ⁇ m or more, and even more preferably 1 ⁇ m or more.
  • ultrafine fibers such as fibers in the range of 8 ⁇ m or less (referred to as microfibers in this disclosure) are particularly preferred because they tend to have a large surface area and high antiviral activity.
  • the fiber length is also not limited, and may be a long fiber length, so-called filament (long fiber), or a short fiber length, so-called staple (short fiber).
  • the thickness of the sheet or film obtained by forming the resin composition of the present disclosure into a sheet or film varies depending on the application, and can be any thickness, but is preferably 1 ⁇ m or more, more preferably 3 ⁇ m or more, even more preferably 5 ⁇ m or more, and particularly preferably 10 ⁇ m or more, and preferably 200 ⁇ m or less, more preferably 150 ⁇ m or less.
  • the terms sheet and film in this disclosure are not used to strictly distinguish between sheets and films, but are used to clarify that they include both, and as long as they have the characteristics of the present disclosure, sheets and films can be interpreted as broadly as possible, and the term sheet includes what is called a plate or board, as long as it has the characteristics of the present disclosure. If it is still necessary to distinguish between sheets and films, within the above range, sheets are usually used when the thickness exceeds about 0.5 mm, and films are usually used when the thickness is up to about 500 ⁇ m.
  • the molded article obtained by melt molding the resin composition of the present disclosure is produced by first forming the antibacterial and antiviral agent into a master batch with a thermoplastic resin, and then blending a diluting resin to produce a thermoplastic resin composition and a molded article thereof.
  • the antibacterial and antiviral agent can be dispersed stably at a high concentration and with good uniformity, resulting in not only excellent antiviral and antibacterial activity, but also long-lasting effects, significantly improved washability, excellent safety to the human body, heat resistance, weather resistance, and water resistance, as well as suppressing the generation of coarse particles (lumps), and by increasing the specific surface area of the particles of the antibacterial and antiviral agent, the activity of the particle surface can be effectively utilized while improving the surface appearance and surface smoothness of the molded article of the particles, and further suppressing film or sheet tearing in the case of a film or sheet, and suppressing thread breakage in the case of fibers.
  • the method for producing a molded article of the present disclosure includes a step of subjecting the thermoplastic resin composition, either directly as a molten product or after being processed into pellets or the like in a conventional manner, to a melt molding machine and melt mixing or melt kneading at a resin set temperature equal to or higher than the melting point.
  • the thermoplastic resin composition melted in the melt molding machine is then molded into a molded article using various known molding methods such as extrusion molding, injection molding, calendar molding, blow molding, vacuum molding, pressure molding, melt spinning, sheet molding, and film molding.
  • Synthesis Example 1 Preparation of fatty acid metal salt (Nd) 224.8 parts by mass of neodecanoic acid and 60.0 parts by mass of neodymium oxide were reacted at 130°C, and then dehydrated under reduced pressure at 130°C. After that, 306.9 parts by mass of cyclohexane were added to obtain 570.0 parts by mass of a neodymium neodecanoate solution. The solvent of the obtained solution was distilled off at 130°C to obtain neodymium neodecanoate (sometimes referred to as "fatty acid metal salt (Nd)"). The neodymium content in the obtained neodymium neodecanoate was 18.7% by mass.
  • the obtained neodymium neodecanoate had a melting point of less than -30°C (not solid at 0 to 45°C).
  • the melting point was measured using a DSC6220 (trade name) manufactured by SII Nanotechnology Co., Ltd., and 10 mg of the sample was weighed in an aluminum container, and the temperature was measured at a heating rate of 10°C/min in the range of -30°C to 200°C, and the temperature was the apex temperature of the melting peak.
  • fatty acid metal salt (Bi) 330.6 parts by mass of 2-ethylhexanoic acid and 125.0 parts by mass of bismuth oxide were reacted at 130°C and then dehydrated under reduced pressure at 130°C, to obtain 439.5 parts by mass of a bismuth 2-ethylhexanoate solution (sometimes referred to as "fatty acid metal salt (Bi)").
  • the bismuth content in the obtained fatty acid metal salt (Bi) was 25% by mass.
  • the melting point of bismuth 2-ethylhexanoate in the fatty acid metal salt (Bi) was less than -30°C (not solid at 0 to 45°C).
  • Production Example 4 A master batch (4) was obtained in the same manner as in Production Example 1, except for two points: "polyethylene terephthalate ("MA-2101M” manufactured by Unitika Ltd., intrinsic viscosity (IV) 0.63), hereinafter abbreviated as “PET resin”) was used instead of “polyethylene resin ("Petrothene” manufactured by Tosoh Corporation)” and the set temperature of the melt kneading was changed from 160°C to 280°C.
  • PET resin polyethylene terephthalate
  • Comparative Production Example 1 A comparative master batch (c1) was obtained in the same manner as in Production Example 1, except that "silver-supported zirconium phosphate (Novalon IV1000, manufactured by Toa Gosei Co., Ltd., silver ion content 10 wt%)" was added instead of "the fatty acid metal salt (Nd) prepared in Synthesis Example 1".
  • Comparative Production Example 2 A comparative master batch (c2) was obtained in the same manner as in Production Example 1, except that the "fatty acid metal salt (Nd) prepared in Synthesis Example 1" was not added.
  • Comparative Production Example 3 A comparative master batch (c3) was obtained in the same manner as in Production Example 4, except that the "fatty acid metal salt (Nd) prepared in Synthesis Example 1" was not added.
  • Examples 1 to 3 Comparative Examples 1 and 2 Production of Films Masterbatches (1) to (3), comparative masterbatches (c1), and (c2) were dry-mixed with PE resin as a diluent resin so that the amount of metal in the film was 1 wt%, and then melt-kneaded with a twin-screw kneader ("TEM" manufactured by Shibaura Machine Co., Ltd.).
  • TEM twin-screw kneader
  • melt film-forming was performed at a film-forming temperature of 160°C using a 20 mm twin-screw extruder (manufactured by Toyo Seiki Co., Ltd., filter installed) connected to a 100 mm wide T-die, to obtain 100 ⁇ m films (1) to (3) and comparative films (c1) and (c2), respectively.
  • Example 4 Comparative Example 3
  • a film (4) and a comparative film (c3) were obtained in the same manner as in Examples 1 to 3 and Comparative Examples 1 and 2, except for the following three points: "Master batch (4)” was used instead of “Master batches (1) to (3) and Comparative master batches (c1) and (c2)", "PET resin” was used instead of "PE resin” as the dilution resin, and the film formation temperature was changed from 160° C. to 280° C.
  • Antibacterial activity value log (number of viable bacteria after incubation per 1 cm2 of untreated sample) - log (number of viable bacteria after incubation per 1 cm2 of antibacterial treated sample)
  • Antibacterial evaluation criteria If the antibacterial activity value is 2.0 or greater, the antibacterial activity is rated “Good”. If 2.0 > antibacterial activity value 1.0 or greater, the antibacterial activity is rated “Correct”. If 1.0 or greater, the antibacterial activity is rated "Poor”.
  • Antiviral activity value log (infectivity value of untreated sample / infectivity value of antibacterial and antiviral treated sample) Evaluation of antiviral properties: If the antiviral activity value is ⁇ 2.0, the antiviral property is evaluated as “ ⁇ ”. If the antiviral activity value is ⁇ 2.0> ⁇ 1.0, the antiviral property is evaluated as “ ⁇ ”. If the antiviral activity value is ⁇ 1.0, the antiviral property is evaluated as “ ⁇ ”.
  • Measurement Example 3 Film Transparency The film obtained above was measured for haze using a haze meter (manufactured by Nippon Denshoku Industries Co., Ltd., device name "NDH 7000II") and evaluated according to the following criteria. Evaluation of transparency: If the haze value is less than +2.0% compared to the haze value of the blank film for PE resin (c2) or the blank film for PET resin (c3), the transparency is evaluated as " ⁇ ". Similarly, if the haze value is more than +2.0% and less than +3.0%, the transparency is evaluated as " ⁇ ”. Similarly, if the haze value is more than +3.0%, the transparency is evaluated as " ⁇ ".
  • the film obtained in Comparative Example 1 had an antibacterial activity value of 2.0 or more (antibacterial), indicating that it had antibacterial properties, and an antiviral activity value of 2.0 or more (antiviral properties), indicating that it had antiviral properties.
  • the film obtained in Comparative Example 1 had a haze value of +3.0% or more compared to the blank film, indicating that it had poor transparency.
  • the film obtained in Comparative Example 1 was pressurized to about 3 MPa, indicating that it had poor film processability.
  • the films obtained in Comparative Examples 2 and 3 had antibacterial activity values of 1.0 or less (no antibacterial properties), indicating that they did not have antibacterial properties, and antiviral activity values of 1.0 or less (no antiviral properties), indicating that they did not have antiviral properties.
  • the films obtained in Examples 1 to 4 had antibacterial activity values of 2.0 or more (antibacterial), and antiviral activity values of 2.0 or more (antiviral).
  • the films obtained in Examples 1 to 4 also had excellent transparency, with haze values of +2.0% or less compared to the blank film.
  • the films obtained in Examples 1 to 4 were all capable of being formed without increasing pressure, and had excellent film processability.
  • the films obtained in Examples 1 to 4 all had excellent surface appearance, with the occurrence of bumps suppressed by surface observation.
  • master batch (3) suppressed thermal degradation during processing compared to master batches (1) and (2), and there was less burning and scorching of the agent, foreign matter thought to result from this, and less decomposition gas.
  • the silver-loaded particles used in the comparative examples had insufficient compatibility with polyethylene resin, and did not maintain transparency when melt-kneaded to form a resin composition. It was also revealed that particle aggregation caused poor appearance of the molded product, and that filter pressure rise occurred during melt processing, resulting in reduced processability. Therefore, shear heat occurred due to kneading with the particles, which led to deterioration of the material, and there was a risk of deterioration in processability and deterioration of physical properties.
  • the fatty acid metal salts or metal complexes used in Examples 1 to 4 have excellent compatibility with both polar and non-polar thermoplastic resins such as polyethylene resin and PET resin, maintain transparency as a resin composition by melt kneading, suppress the generation of aggregation (particles), and do not generate bumps due to aggregation, resulting in excellent appearance of molded products, and not only suppress filter pressure rise during processing, but also suppress clogging of nozzles and dies, thereby suppressing the occurrence of thread breakage, film rupture, etc., and have excellent processability and can improve productivity. It was also revealed that suppressing filter pressure rise during processing can suppress heat generation during molding processing, suppress material deterioration, and suppress deterioration of physical properties.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

L'invention concerne un article moulé ayant d'excellentes activités antibactériennes et antivirales et son procédé de production avec une bonne aptitude au traitement, un mélange maître qui permet de fournir l'article moulé et le procédé de production, une composition de résine thermoplastique et ses procédés de production. Plus spécifiquement, l'invention concerne : un mélange maître qui contient un agent antibactérien/antiviral qui est au moins un élément choisi dans le groupe constitué par un sel métallique d'acide gras, un complexe métallique d'un ligand contenant un hétéroatome et un ion métallique, et un complexe métallique d'un ligand contenant un hétéroatome et d'un sel métallique d'acide gras, le métal dans chacun du sel métallique d'acide gras, du complexe métallique d'un ligand de composé contenant un hétéroatome et d'un ion métallique, et le complexe métallique d'un ligand de composé contenant un hétéroatome et d'un sel métallique d'acide gras étant indépendamment un lanthanide, du bismuth, du manganèse, du magnésium, du plomb, de l'yttrium, du cobalt ou du cuivre ; une composition de résine préparée par malaxage à l'état fondu du mélange maître avec une résine thermoplastique ; un article moulé produit par moulage à l'état fondu de la composition de résine ; et ses procédés de production.
PCT/JP2023/043751 2022-12-13 2023-12-07 Mélange maître, composition de résine, article moulé et ses procédés de production WO2024128107A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-198522 2022-12-13
JP2022198522 2022-12-13

Publications (1)

Publication Number Publication Date
WO2024128107A1 true WO2024128107A1 (fr) 2024-06-20

Family

ID=91484957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/043751 WO2024128107A1 (fr) 2022-12-13 2023-12-07 Mélange maître, composition de résine, article moulé et ses procédés de production

Country Status (1)

Country Link
WO (1) WO2024128107A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08165212A (ja) * 1994-12-14 1996-06-25 Taki Chem Co Ltd 抗菌剤の製造方法及び抗菌剤
JPH08302028A (ja) * 1995-05-10 1996-11-19 Nippon Mizushiyori Giken:Kk 抗菌マスターバッチ
JPH091698A (ja) * 1995-06-19 1997-01-07 Oorora:Kk 抗菌性キートップ
CN106367840A (zh) * 2016-11-18 2017-02-01 大连海事大学 一种纤维用掺杂纳米无机粉体的抗菌母粒及其制备方法
JP2019524905A (ja) * 2016-06-06 2019-09-05 テューリンギッシェス・インスティトゥート・フューア・テクスティル−ウント・クンストストッフ−フォルシュング・エー・ファウ 生物活性を有するポリエステルおよびポリオレフィン成形化合物ならびにそれから製造される成形体
JP2020169387A (ja) * 2019-04-03 2020-10-15 東洋製罐グループホールディングス株式会社 金属銅微粒子粉末及びその製造方法
WO2021200808A1 (fr) * 2020-03-30 2021-10-07 住化エンバイロメンタルサイエンス株式会社 Agent antiviral
JP2022165893A (ja) * 2021-04-20 2022-11-01 南亞塑膠工業股▲分▼有限公司 透明抗菌フィルム及びその製造方法
WO2022264768A1 (fr) * 2021-06-15 2022-12-22 Dic株式会社 Agent antibactérien-antiviral, composition de revêtement antibactérienne-antivirale, stratifié, composition de résine antibactérienne-antivirale et article moulé

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08165212A (ja) * 1994-12-14 1996-06-25 Taki Chem Co Ltd 抗菌剤の製造方法及び抗菌剤
JPH08302028A (ja) * 1995-05-10 1996-11-19 Nippon Mizushiyori Giken:Kk 抗菌マスターバッチ
JPH091698A (ja) * 1995-06-19 1997-01-07 Oorora:Kk 抗菌性キートップ
JP2019524905A (ja) * 2016-06-06 2019-09-05 テューリンギッシェス・インスティトゥート・フューア・テクスティル−ウント・クンストストッフ−フォルシュング・エー・ファウ 生物活性を有するポリエステルおよびポリオレフィン成形化合物ならびにそれから製造される成形体
CN106367840A (zh) * 2016-11-18 2017-02-01 大连海事大学 一种纤维用掺杂纳米无机粉体的抗菌母粒及其制备方法
JP2020169387A (ja) * 2019-04-03 2020-10-15 東洋製罐グループホールディングス株式会社 金属銅微粒子粉末及びその製造方法
WO2021200808A1 (fr) * 2020-03-30 2021-10-07 住化エンバイロメンタルサイエンス株式会社 Agent antiviral
JP2022165893A (ja) * 2021-04-20 2022-11-01 南亞塑膠工業股▲分▼有限公司 透明抗菌フィルム及びその製造方法
WO2022264768A1 (fr) * 2021-06-15 2022-12-22 Dic株式会社 Agent antibactérien-antiviral, composition de revêtement antibactérienne-antivirale, stratifié, composition de résine antibactérienne-antivirale et article moulé

Similar Documents

Publication Publication Date Title
US8648132B2 (en) Nanocomposite method of manufacture
EP1746136B1 (fr) Composition de résine biodégradable
JP3958215B2 (ja) ヘキサヒドロフタル酸シス−２ナトリウム塩組成物およびその組成物を含んでなる有核ポリマー
TWI599621B (zh) 用於連續製備聚合物組合物的方法及根據該方法獲得的聚合物組成物，聚合物產物，用於製備聚合物產物之聚合物組成物的用途及用於製備聚合物組成物之呈漿料形式的填料的用途
US20150218390A1 (en) Polymeric materials with antifouling, biocidal, antiviral and antimicrobial properties; elaboration method and its uses
EP3660095A1 (fr) Composition polymère biodégradable et application associée
TW201022363A (en) Silver polyamide composite
KR101946742B1 (ko) 폴리프로필렌의 압출 방법
EP3224310B1 (fr) Procédé d'extrusion de polypropylène
CN109553882B (zh) 一种聚氯乙烯抗菌材料及其制备方法和应用
JP5182911B2 (ja) 銀及び有機酸アニオン含有アルミニウム硫酸塩水酸物粒子よりなる抗菌剤およびその利用
EP2653499A1 (fr) Composition de résine de poly(acide lactique)
WO2024128107A1 (fr) Mélange maître, composition de résine, article moulé et ses procédés de production
JP6864522B2 (ja) ペレット
JP6709782B2 (ja) ハイドロタルサイト粒子を用いた透明合成樹脂成形品の製造法
JP6944265B2 (ja) フィルム
JP5295929B2 (ja) ポリ塩化ビニリデン樹脂組成物、その製造方法、及び該樹脂組成物から形成された成形品
TW200306960A (en) Antibacterial glass compositions, antibacterial resin compositions and a method for the preparation thereof
JP2013212937A (ja) 層状複水酸化物の製造方法
JP2014009266A (ja) ポリ乳酸樹脂組成物からなる熱成形品
TW202146553A (zh) 母料、樹脂組成物、成形品及彼等之製造方法
JP6106380B2 (ja) 抗菌性マスターバッチ及びそれを用いた成形体
JP2016216573A (ja) 樹脂組成物とこれを成形加工した樹脂成形体及び樹脂組成物の製造方法
CN110607083A (zh) 一种医疗塑料粒子配方
KR101824189B1 (ko) 아연 카르복실산염의 수화물의 제조 방법, 이로부터 제조된 아연 카르복실산염의 수화물 및 상기 아연 카르복실산염의 수화물을 포함한 향균 플라스틱 소재

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23903395

Country of ref document: EP

Kind code of ref document: A1